These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 17476684

  • 21. Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
    Shah U, Boyle CD, Chackalamannil S, Neustadt BR, Lindo N, Greenlee WJ, Foster C, Arik L, Zhai Y, Ng K, Wang S, Monopoli A, Lachowicz JE.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4199-203. PubMed ID: 18562199
    [Abstract] [Full Text] [Related]

  • 22. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.
    Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M.
    J Neurol Sci; 2006 Oct 25; 248(1-2):48-52. PubMed ID: 16780890
    [Abstract] [Full Text] [Related]

  • 23. Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
    Metz GA, Piecharka DM, Kleim JA, Whishaw IQ.
    Brain Res; 2004 Nov 05; 1026(1):126-35. PubMed ID: 15476704
    [Abstract] [Full Text] [Related]

  • 24. Effect of free radicals on adenosine A(2A) and dopamine D2 receptors in the striatum of young adult and aged rats.
    Alfaro TM, Vigia E, Oliveira CR, Cunha RA.
    Neurochem Int; 2004 Oct 05; 45(5):733-8. PubMed ID: 15234116
    [Abstract] [Full Text] [Related]

  • 25. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
    Carta AR, Tabrizi MA, Baraldi PG, Pinna A, Pala P, Morelli M.
    Exp Neurol; 2003 Dec 05; 184(2):679-87. PubMed ID: 14769359
    [Abstract] [Full Text] [Related]

  • 26. Repetitive vibrissae-elicited forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease.
    Anstrom KK, Schallert T, Woodlee MT, Shattuck A, Roberts DC.
    Behav Brain Res; 2007 May 16; 179(2):183-91. PubMed ID: 17374405
    [Abstract] [Full Text] [Related]

  • 27. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
    Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, Cohen-Williams ME, Higgins GA, Impagnatiello F, Nicolussi E, Parra LE, Foster C, Zhai Y, Neustadt BR, Stamford AW, Parker EM, Reggiani A, Hunter JC.
    J Pharmacol Exp Ther; 2009 Jul 16; 330(1):294-303. PubMed ID: 19332567
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake.
    Popoli P, Reggio R, Pèzzola A.
    Neuropsychopharmacology; 2000 May 16; 22(5):522-9. PubMed ID: 10731627
    [Abstract] [Full Text] [Related]

  • 33. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM.
    J Pharmacol Exp Ther; 2012 Feb 16; 340(2):404-21. PubMed ID: 22088953
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.
    Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M.
    Exp Neurol; 2006 Nov 16; 202(1):255-7. PubMed ID: 16808917
    [Abstract] [Full Text] [Related]

  • 37. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM, Browne SE, Jayaraman S, Bleickardt CJ, Hodge LM, Lis E, Yao L, Rittle SL, Innocent N, Mullins DE, Boykow G, Reynolds IJ, Hill D, Parker EM, Hodgson RA.
    Eur J Pharmacol; 2014 Apr 05; 728():31-8. PubMed ID: 24486705
    [Abstract] [Full Text] [Related]

  • 38. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.
    Melani A, Cipriani S, Vannucchi MG, Nosi D, Donati C, Bruni P, Giovannini MG, Pedata F.
    Brain; 2009 Jun 05; 132(Pt 6):1480-95. PubMed ID: 19359287
    [Abstract] [Full Text] [Related]

  • 39. A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity.
    Belcastro V, Tozzi A, Tantucci M, Costa C, Di Filippo M, Autuori A, Picconi B, Siliquini S, Luchetti E, Borsini F, Calabresi P.
    Exp Neurol; 2009 May 05; 217(1):231-4. PubMed ID: 19416678
    [Abstract] [Full Text] [Related]

  • 40. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P.
    Neurobiol Dis; 2007 Nov 05; 28(2):197-205. PubMed ID: 17720507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.